drugset
drugset / Trial / NCT04237831

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

NCT04237831 ↗

Phase 1 Completed 30 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelTreatment

Summary

A study to evaluate the drug effect, safety, and tolerability of BMS-986259 in participants with different levels of kidney function

Timeline

Start
2020-02-26
Primary completion
2021-07-16
Completion
2021-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986259 Unknown — —

Indications

kidney failure